<DOC>
	<DOCNO>NCT01266720</DOCNO>
	<brief_summary>The purpuse study assess toxicity angiogenic peptide vaccine therapy gemcitabine treat HLA-A*0201 restricted patient non-resectable pancreatic cancer .</brief_summary>
	<brief_title>HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine Patient Pancreatic Cancer ( Phase1 )</brief_title>
	<detailed_description>The prognosis pancreatic cancer extremely poor even extensive surgery , chemotherapy radiation . It require development new treatment modality . Immunotherapy one encourage modality cancer patient . The investigator assess toxicity immune responsiveness .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>locally advanced metastatic pancreatic cancer preclude curative surgical resection recurrent pancreatic cancer Measurable disease CT scan ECOG performance status 02 Life expectancy &gt; 3 month laboratory value follow : 2,000/mm3 &lt; WBC &lt; 15,000/mm3 , Platelet count &gt; 75,000/mm3 , Total Bilirubin &lt; 1.5 mg/dl , Asparate transaminase &lt; 150IU/L , Alanine transaminase &lt; 150 IU/L , Creatinine &lt; 3.0mg/dl HLAA*0201 Able willing give valid write infromed consent Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) Breastfeeder Active uncontrolled infection Prior chemotherapy , radiation therapy , immunotherapy within 4 week Serious uncured wound Active uncontrolled malignancy Steroids immunosuppressing agent dependent status Interstitial pneumonia Ileus Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>peptide vaccine</keyword>
	<keyword>VEGFR</keyword>
	<keyword>gemcitabine</keyword>
</DOC>